HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Karel Ulbrich Selected Research

N-(2-hydroxypropyl)methacrylamide

12/2016Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
11/2016Biodegradable Micellar HPMA-Based Polymer-Drug Conjugates with Betulinic Acid for Passive Tumor Targeting.
2/2016The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia.
11/2015Photodynamic therapy and imaging based on tumor-targeted nanoprobe, polymer-conjugated zinc protoporphyrin.
1/2014Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage.
12/2013Dual fluorescent HPMA copolymers for passive tumor targeting with pH-sensitive drug release II: impact of release rate on biodistribution.
3/2013Polymer therapeutics with a coiled coil motif targeted against murine bcl1 leukemia.
12/2012HPMA copolymer-doxorubicin conjugates: The effects of molecular weight and architecture on biodistribution and in vivo activity.
10/2011Antitumor activity of IL-2/anti-IL-2 mAb immunocomplexes exerts synergism with that of N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugate due to its low immunosuppressive activity.
9/2011Biodegradable star HPMA polymer-drug conjugates: Biodegradability, distribution and anti-tumor efficacy.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Karel Ulbrich Research Topics

Disease

67Neoplasms (Cancer)
07/2019 - 01/2003
8Infections
11/2013 - 02/2008
8T-Cell Lymphoma (Lymphoma, T Cell)
12/2012 - 10/2003
6Carcinoma (Carcinomatosis)
11/2016 - 08/2002
3Breast Neoplasms (Breast Cancer)
12/2018 - 08/2003
3Prostatic Neoplasms (Prostate Cancer)
02/2016 - 07/2010
3Leukemia
03/2013 - 05/2002
2Colonic Neoplasms (Colon Cancer)
12/2018 - 11/2015
2Melanoma (Melanoma, Malignant)
10/2011 - 10/2010
2Ovarian Neoplasms (Ovarian Cancer)
03/2008 - 02/2008
1Lung Neoplasms (Lung Cancer)
09/2018
1Neuroblastoma
10/2016
1Neoplasm Metastasis (Metastasis)
02/2016
1Arthritis (Polyarthritis)
01/2014
1Sarcoma (Soft Tissue Sarcoma)
02/2013
1Kidney Neoplasms (Kidney Cancer)
10/2011
1Bloom Syndrome
08/2011

Drug/Important Bio-Agent (IBA)

37PolymersIBA
12/2018 - 09/2007
36hydroxypropyl methacrylateIBA
01/2018 - 05/2002
35Pharmaceutical PreparationsIBA
12/2018 - 05/2002
24Doxorubicin (Adriamycin)FDA LinkGeneric
01/2018 - 08/2003
17N-(2-hydroxypropyl)methacrylamideIBA
12/2016 - 08/2003
9MicellesIBA
01/2018 - 10/2009
8Drug CarriersIBA
01/2018 - 07/2009
6pirarubicinIBA
12/2018 - 01/2014
6methacrylamideIBA
01/2018 - 10/2009
6Cytostatic AgentsIBA
11/2016 - 09/2006
5LigandsIBA
03/2013 - 04/2008
4Therapeutic UsesIBA
12/2018 - 02/2013
4DuxonIBA
09/2018 - 02/2013
4HydrazonesIBA
01/2018 - 01/2014
4Monoclonal AntibodiesIBA
03/2013 - 10/2003
3Biological ProductsIBA
12/2016 - 12/2013
3AcidsIBA
02/2015 - 04/2004
3Peptides (Polypeptides)IBA
03/2013 - 12/2005
3OligopeptidesIBA
12/2012 - 12/2009
2XenonIBA
09/2018 - 11/2015
21-phenyl-3,3-dimethyltriazene (PDT)IBA
09/2018 - 11/2015
2SolutionsIBA
01/2018 - 02/2013
2ProdrugsIBA
01/2018 - 01/2014
2AnthracyclinesIBA
10/2016 - 08/2011
2Antineoplastic Agents (Antineoplastics)IBA
05/2016 - 12/2010
2zinc protoporphyrinIBA
11/2015 - 02/2013
2Liposomes (Liposome)IBA
01/2014 - 07/2009
2HydrazinesIBA
01/2014 - 12/2005
2CholesterolIBA
01/2013 - 08/2012
2ErbB Receptors (EGF Receptor)IBA
12/2012 - 02/2008
2BuffersIBA
09/2011 - 04/2011
2DNA (Deoxyribonucleic Acid)IBA
08/2011 - 06/2011
2AntigensIBA
11/2010 - 11/2009
2Radioisotopes (Radionuclides)IBA
08/2010 - 10/2009
2Immunoglobulins (Immunoglobulin)IBA
09/2007 - 08/2003
1AzoxymethaneIBA
12/2018
1anthraceneIBA
12/2018
1Dextran SulfateIBA
12/2018
1Photosensitizing Agents (Photosensitizers)IBA
09/2018
1pyropheophorbide aIBA
09/2018
1Arginine (L-Arginine)FDA Link
01/2018
1Betulinic AcidIBA
11/2016
1Protons (Proton)IBA
02/2016
1CarcinogensIBA
11/2015
1ellipticineIBA
02/2015
1NGR peptideIBA
02/2014
1arginyl-glycyl-aspartic acidIBA
02/2014
1Dexamethasone (Maxidex)FDA LinkGeneric
01/2014
1GlucocorticoidsIBA
01/2014
1Mitomycin (Mitomycin-C)FDA LinkGeneric
12/2013
1Singlet OxygenIBA
02/2013
1butyleneIBA
01/2013
1bionoleIBA
01/2013
1liposomal doxorubicin (Doxil)FDA Link
03/2012
1Interleukin-12 (IL 12)IBA
10/2011
1InterleukinsIBA
10/2011
1Carbonic Anhydrase IXIBA
10/2011
1Immunoglobulin FragmentsIBA
10/2011
1SuspensionsIBA
09/2011
1Cytochrome P-450 CYP2C9IBA
09/2011
1Cytochrome P-450 CYP2B6 (CYP2B6)IBA
09/2011
1Cytochrome P-450 CYP2C8IBA
09/2011
1Cytochrome P-450 CYP2E1 (CYP2E1)IBA
09/2011
1Cytochrome P-450 CYP2D6 (CYP2D6)IBA
09/2011
1Cytochrome P-450 CYP1A2 (CYP1A2)IBA
09/2011
1Cytochrome P-450 CYP3AIBA
09/2011
1Cytochrome P-450 CYP2C19IBA
09/2011
1CytochromesIBA
09/2011
1Formaldehyde (Formol)FDA Link
08/2011
1AN 204 (AN 201)IBA
08/2011
1bacteriophage T7 RNA polymerase (T7 RNA polymerase)IBA
08/2011
1Type II DNA Topoisomerases (Topoisomerase II)IBA
08/2011
1Intercalating AgentsIBA
06/2011

Therapy/Procedure

21Therapeutics
07/2019 - 05/2002
6Drug Therapy (Chemotherapy)
12/2011 - 08/2003
3Radiotherapy
02/2016 - 02/2007
2Photochemotherapy (Photodynamic Therapy)
09/2018 - 11/2015
2Intravenous Administration
11/2013 - 10/2010
1Precision Medicine
09/2018
1Endoscopes
09/2018
1Combined Modality Therapy
02/2016
1Microbubbles
11/2013
1Aftercare (After-Treatment)
08/2013